Virotherapy and Gene Therapy in Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 15 May 2024 | Viewed by 401
Special Issue Editor
Special Issue Information
Dear Colleagues,
Recent advancements in oncolytic viral therapy and gene therapy for cancer have shown great potential for improving the survival rates and quality of life of cancer patients. Clinical studies have demonstrated the effectiveness of OVs for various types of cancer. Repurposing drugs that have already been approved for other purposes and combining multiple anti-cancer drugs, including OVs, immune checkpoint inhibitors, tumor-treating fields and radiation therapy at suboptimal doses are potential strategies for quickly providing new cancer treatments. Gene therapy is another promising field, involving the delivery of therapeutic genes into cancer cells. Combining oncolytic viral therapy and gene therapy has the potential to revolutionize cancer treatment by developing personalized therapies tailored to individual genetic profiles. The future of these fields is bright, and continued research is encouraged to advance knowledge and improve cancer treatment.
We are excited to announce that our journal is currently accepting original research articles and reviews on a range of topics related to cancer treatment. We cordially invite you to submit your high-quality research articles on any of the following topics:
- Oncolytic and immunomodulatory activity of live attenuated viral vaccines;
- In situ vaccination of immunovirotherapy;
- Radiation therapy combined with oncolytic viral therapy;
- Oncolytic virus design and engineering;
- Viral delivery of therapeutic proteins;
- Cancer gene therapy;
- Minimally invasive Cancer imaging using viral vectors;
- Oncolytic virus delivery;
- Systemic immunovirotherapy combined with immune checkpoint inhibitors;
- Combination natural products and oncolytic viruses;
- Targeting the stroma in Cancer;
- Metastases targeting;
- Combination therapies;
- Combination of cellular therapy and oncolytic viral therapies.
Dr. Bolni Marius Nagalo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunovirotherapy
- cancer gene therapy
- radiation therapy
- natural products
- stroma in cancer
